Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,240

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Improved survival in multiple myeloma and the impact of novel therapies

Open access
Kumar, Shaji K., Rajkumar, S. Vincent, Dispenzieri, Angela, Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Zeldenrust, Steven R., Dingli, David, Russell, Stephen J., Lust, John A., Greipp, Philip R., Kyle, Robert A., Gertz, Morie A.·2008·Blood
DOI 10.1182/blood-2007-10-116129
Open this paper in CoChat — free account

Abstract

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem-cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P < .001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P < .001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-10-116129

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 28

  1. Parkin, 2005, Global cancer statistics, 2002., CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74 · DOI · Paper page
  2. Osgood, 1960, The survival time of patients with plasmocytic myeloma., Cancer Chemother Rep, 9, 1
  3. Bergsagel, 1962, Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma, IV: L-Phenylalanine mustard (NSC-8806)., Cancer Chemother Rep, 21, 87
  4. McElwain, 1983, High-dose intravenous melphalan for plasma-cell leukaemia and myeloma., Lancet, 2, 822, 10.1016/S0140-6736(83)90739-0 · DOI · Paper page
  5. Attal, 1996, Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome., N Engl J Med, 335, 91, 10.1056/NEJM199607113350204 · DOI · Paper page
  6. Rajkumar, 2005, Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma., Blood, 106, 4050, 10.1182/blood-2005-07-2817 · DOI · Paper page
  7. Kumar, 2005, Drug insight: thalidomide as a treatment for multiple myeloma., Nat Clin Pract Oncol, 2, 262, 10.1038/ncponc0174 · DOI
  8. Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma., N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
  9. Kumar, 2006, Progress in the treatment of multiple myeloma., Lancet, 367, 791, 10.1016/S0140-6736(06)68311-6 · DOI
  10. Singhal, 1999, Antitumor activity of thalidomide in refractory multiple myeloma., N Engl J Med, 341, 1565, 10.1056/NEJM199911183412102 · DOI · Paper page
  11. Kumar, 2003, Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma., Mayo Clin Proc, 78, 34, 10.4065/78.1.34 · DOI
  12. Rajkumar, 2000, Thalidomide in the treatment of relapsed multiple myeloma., Mayo Clin Proc, 75, 897, 10.4065/75.9.897 · DOI · Paper page
  13. Barlogie, 2001, Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients., Blood, 98, 492, 10.1182/blood.V98.2.492 · DOI · Paper page
  14. Blade, 2001, Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas., Br J Haematol, 113, 422, 10.1046/j.1365-2141.2001.02765.x · DOI
  15. Tosi, 2001, Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation., Haematologica, 86, 409
  16. Kumar, 2004, Clinical course of patients with relapsed multiple myeloma., Mayo Clin Proc, 79, 867, 10.4065/79.7.867 · DOI · Paper page
  17. Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma., N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
  18. Dimopoulos, 2005, Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]., Blood, 106, 6a, 10.1182/blood.V106.11.6.6 · DOI
  19. Weber, 2006, Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function., ASH Annual Meeting Abstracts, 108, 3547
  20. Jagannath, 2005, Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma., Br J Haematol, 129, 776, 10.1111/j.1365-2141.2005.05540.x · DOI · Paper page
  21. Rajkumar, 2007, Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group., J Clin Oncol (Meeting Abstracts), 25, LBA8025, 10.1200/jco.2007.25.18_suppl.lba8025 · DOI
  22. Berenson, 1998, Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group., J Clin Oncol, 16, 593, 10.1200/JCO.1998.16.2.593 · DOI · Paper page
  23. Kristinsson, 2007, Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003., J Clin Oncol, 25, 1993, 10.1200/JCO.2006.09.0100 · DOI · Paper page
  24. Jawed, 2007, Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis., J Clin Oncol, 25, 8019, 10.1200/jco.2007.25.18_suppl.8019 · doi:10.1200/jco.2007.25.18_suppl.8019
  25. 1998, Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group., J Clin Oncol, 16, 3832, 10.1200/JCO.1998.16.12.3832 · DOI · Paper page
  26. Fermand, 2005, High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe., J Clin Oncol, 23, 9227, 10.1200/JCO.2005.03.0551 · DOI · Paper page
  27. Blade, 2005, High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA., Blood, 106, 3755, 10.1182/blood-2005-03-1301 · DOI · Paper page
  28. Richardson, 2003, A phase 2 study of bortezomib in relapsed, refractory myeloma., N Engl J Med, 348, 2609, 10.1056/NEJMoa030288 · DOI · Paper page

Cited by

See all 2,240

Metadata

Authors
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., Greipp, P. R., Kyle, R. A., & Gertz, M. A.
Venue
Blood
Publisher
American Society of Hematology
Published
2008-03-01
Volume
111
Issue
5
Pages
2516-2520
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2007-10-116129
OpenAlex
W2066800926
Cited by
2,240
References
8
FWCI
45.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved survival in multiple myeloma and the impact of novel therapies. https://app.cochat.ai/papers/10.1182/blood-2007-10-116129
The paper
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., Greipp, P. R., Kyle, R. A., & Gertz, M. A. (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood. https://doi.org/10.1182/blood-2007-10-116129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.